Submitted by Anonymous (not verified) on 6 February 2025 - 15:17
Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised
Source: